The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Interim results of a randomized phase II study with window-design to evaluate antitumor activity of the survivin antisense oligonucleotide (ASO) LY2181308 in combination with docetaxel for first-line treatment of castrate-resistant prostate cancer (CRPC).
P. J. Wiechno
No relevant relationships to disclose
P. Chlosta
No relevant relationships to disclose
J. Smok-Kalwat
No relevant relationships to disclose
J. Pikilel
No relevant relationships to disclose
D. H. Henry
Consultant or Advisory Role - Amgen; Cobi; Watson Pharmaceuticals
Honoraria - Amgen; Cobi; Watson Pharmaceuticals
Research Funding - Amgen; Cobi; Watson Pharmaceuticals
D. F. Christianson
No relevant relationships to disclose
B. G. Somer
Honoraria - Lilly
B. Mellado
No relevant relationships to disclose
I. Duran
No relevant relationships to disclose
D. E. Castellano
No relevant relationships to disclose
S. Callies
Employment or Leadership Position - Lilly
V. Andre
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
K. Hurt
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
M. M. F. Lahn
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
M. Stöckle
No relevant relationships to disclose
C. Reuter
Consultant or Advisory Role - Amgen
B. Heinrich
No relevant relationships to disclose